The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities

NCT ID: NCT07086833

Last Updated: 2025-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-30

Study Completion Date

2027-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if changing cysteine levels in the diet can influence how the body processes cysteine in Black and White individuals aged 45-75 with a history of non-cancerous polyps. The main questions it aims to answer are:

* At the beginning of the study, do Black participants have higher levels of cortisol (a stress hormone) and compounds made from cysteine in their blood when compared to White participants?
* Does eating less cysteine lower the body's natural cysteine activity and lead to less gut bacteria that break down cysteine?
* Does eating less cysteine lead to less inflammation in the gut and lower levels of markers of inflammation in the blood?

Research will compare a high cysteine diet and a low cysteine diet, and each participant will eat both diets.

Participants will be in the study for 11 weeks and 2 days. Over the course of the study, participants will:

* Eat a high cysteine diet for 3 weeks, and a low cysteine diet for 3 weeks
* Eat a moderate cysteine diet for 1 week before each study diet
* Complete surveys
* Provide blood, stool, and saliva samples
* Maintain food logs

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Risk Colorectal Cancer Prevention Colorectal Cancer Diet Modification Dietary Intervention Cancer Prevention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized controlled cross-over feeding trial
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High cysteine diet

Participants will eat a diet higher in cysteine, relying on more animal based protein.

Group Type EXPERIMENTAL

High Cysteine Diet

Intervention Type OTHER

A diet high in cysteine, about 3 g/1000 kcal.

Low cysteine diet

Participants will eat a diet lower in cysteine, relying on more plant based protein.

Group Type EXPERIMENTAL

Low Cysteine Diet

Intervention Type OTHER

A diet low in cysteine, about 1.4 g/1000 kcal.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low Cysteine Diet

A diet low in cysteine, about 1.4 g/1000 kcal.

Intervention Type OTHER

High Cysteine Diet

A diet high in cysteine, about 3 g/1000 kcal.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 45-75
* Up to date with CRC screening colonoscopy with a high risk of CRC, defined as a history of 3 or more adenomatous polyps (APs) or an AP \>1 cm in the past 5 years
* Identify as Black or Non-Hispanic White
* If female, no menstrual period for at least six months
* Willingness to donate oral wash and stool samples
* Willingness to complete 24-hour dietary recalls

Exclusion Criteria

* Antibiotic use within the last 6 months
* Abnormal gastrointestinal transit
* A history of organ transplantation
* Use of illicit drugs, combustible tobacco, or dietary supplements
* Pre- or probiotics within the last two months
* A history of cancer treatment within the past 12 months
* CRC or a genetic predisposition to CRC
* A baseline body weight \> 450 lbs
* Weight gain or loss \> 4 kg 3 months prior to study
* Significant food allergies, food preferences or therapeutic or vegetarian diets
* Menstrual cycle within the last 6 months
* Antibiotics in the last 2 months
* Cannot keep a food record for 7 consecutive days during screening after detailed instruction
* Significant medical conditions
* History of eating disorders
* Alcoholism
* Individuals under the age of 18
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Cancer Society, Inc.

OTHER

Sponsor Role collaborator

Indiana University

OTHER

Sponsor Role collaborator

Purdue University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Patricia Wolf

Dr. Patricia Wolf, Assistant Professor, Department of Nutrition Science

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Clinical Research Center

Indianapolis, Indiana, United States

Site Status NOT_YET_RECRUITING

Purdue Clinical Research Center

West Lafayette, Indiana, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Patricia G Wolf, PhD, RD

Role: CONTACT

765-494-1860

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ariana Moffitt, MPH

Role: primary

765-494-1860

Ariana Moffitt, MPH

Role: primary

765-494-1860

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RSG-23-1154989-01-CSCT

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

IRB-2023-1426

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Colorectal Cancer Screening in Cystic Fibrosis
NCT05362344 ACTIVE_NOT_RECRUITING
Prebiotics in Rectal Cancer
NCT05516641 UNKNOWN NA